DelfaGLP-1 Atlas

Lead sponsor

LMC Diabetes & Endocrinology Ltd.

5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

5

Trials led

1

Active

6,000

Total enrollment

4

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 4
1
Not applicable
4

Trials by status

Not yet recruiting
1
Completed
4

Trials led

ALT—not applicableCompleted4,000
Real-world Health Outcomes in Canadian Patients Using Semaglutide—not applicableCompleted1,133
SEMA-CKMBMI ≥27not applicableNot yet recruiting400
Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney DiseaseHbA1c ≥7.5%not applicableCompleted348
VARIATION 2 SABMI 20-40Ph 4Completed119